Welcome to our dedicated page for NYXOAH S A SEC filings (Ticker: NYXH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nyxoah SA (NYXH) files reports with the U.S. Securities and Exchange Commission as a foreign private issuer, providing detailed information on its Genio hypoglossal neurostimulation system for obstructive sleep apnea (OSA), financing transactions and risk factors. On Stock Titan’s SEC filings page, you can review these documents alongside AI-powered summaries that help explain their content in plain language.
Nyxoah uses Form 6-K current reports to furnish press releases and transaction details to U.S. investors. Recent 6-K filings describe private placements and registered direct offerings of ordinary shares, a subscription agreement for amortizing senior unsecured convertible notes, and the intended use of proceeds to support U.S. and international commercialization of the Genio system, fund clinical research, and finance upgrades and cost reduction initiatives. Other 6-Ks attach quarterly financial reports, preliminary results, and disclosures about FDA approval of the Genio system for a defined subset of adult patients with moderate to severe OSA.
Filings also contain extensive risk factor discussions, including sections on intellectual property litigation risk, market acceptance of the Genio system, and regulatory pathways in the United States and abroad. Additional exhibits cover underwriting agreements, legal opinions related to securities offerings, and information incorporated by reference into Nyxoah’s shelf registration statements on Form F-3 and equity compensation registration statements on Form S-8.
On this page, AI-generated highlights can point out key elements in Nyxoah’s filings, such as financing terms, reported cash position, regulatory milestones, and legal proceedings, while links to the full EDGAR documents allow for deeper review. Investors can also monitor how new 6-K submissions update or supplement existing registration statements and risk disclosures over time.
Nyxoah SA furnished a report highlighting preliminary, unaudited financial and operating results for the fourth quarter and full year 2025 and providing revenue guidance commentary for the first quarter of 2026. The Company’s first full quarter of U.S. commercialization after FDA approval generated what management describes as strong momentum, with early U.S. patients seeing positive outcomes, a waiting list for additional surgeon training, and patients already scheduled for implants.
Management stated that global revenue exceeded
Nyxoah SA is offering 1,215,964 ordinary shares at $4.6304 (€4.00) per share, raising gross proceeds of about $5.6 million and estimated net proceeds of $5.5 million (€4.8 million). The shares are sold directly to investors without an underwriter, and trade on Nasdaq and Euronext Brussels under “NYXH.” Nyxoah plans to use the cash to support the U.S. launch and international commercialization of its Genio system for obstructive sleep apnea, fund clinical data generation and physician-led studies, advance R&D, build a pipeline in OSA monitoring and diagnostics, and for general corporate purposes.
Alongside this deal, the company has arranged a €17.0 million private placement of 4,265,714 ordinary shares at €4.00 and a separate offering of up to €45.0 million in amortizing senior unsecured convertible notes, expected to yield about €41.4 million in gross proceeds. As of September 30, 2025, Nyxoah had 37,544,782 ordinary shares outstanding, which would increase to 38,760,746 after this offering, before giving effect to the private placement, notes conversion, or warrant exercises.
Nyxoah SA announced a multi-part financing to support commercialization of its Genio system and ongoing R&D. The company agreed to a private placement of ordinary shares at €4.00 per share for aggregate gross proceeds of approximately €17.0 million, expected to close on or about November 18, 2025, subject to customary conditions.
Separately, Nyxoah entered a registered direct offering of ordinary shares at U.S.$4.6304 per share for aggregate gross proceeds of approximately U.S.$5.6 million, also expected to close on or about November 18, 2025. In addition, the company signed a convertible notes deal for up to €45.0 million aggregate principal amount at an 8.0% original issue discount, issued in two €22.5 million tranches; assuming both tranches, gross proceeds total approximately €41.4 million. The notes bear 6.5% interest, mature three years from issuance, and amortize quarterly over 12 installments, with optional share-settled payments priced per the bond instrument. Initial conversion pricing is set at 125% of the private placement price for the first tranche.
Proceeds across the transactions are designated for U.S. and ex-U.S. commercialization, clinical data, R&D and cost reductions, pipeline and collaborations, and general corporate purposes.
Nyxoah furnished a Form 6-K stating that on November 13, 2025 it announced its unaudited third quarter 2025 results. Those results are contained in a Third Quarter 2025 report attached as Exhibit 99.1. The company also states that the information in Exhibit 99.1 is incorporated by reference into its existing registration statements on Form S-8 and Form F-3, so that these offerings will automatically reflect the latest disclosed information.
Nyxoah SA has entered into an underwriting agreement with Morgan Stanley, Stifel and Cantor Fitzgerald to conduct an underwritten public offering of ordinary shares under its existing shelf registration on Form F-3. The company has granted the underwriters a 30-day option to buy additional shares and expects the offering to close around September 23, 2025, subject to customary conditions.
Nyxoah anticipates receiving net proceeds from this equity raise, after underwriting fees and expenses, and states that, based on current plans, the cash from this offering together with existing cash, cash equivalents and financial assets should be sufficient to fund operating expenses and capital expenditures for an extended period, as outlined in the cash runway discussion. The filing also notes standard indemnification provisions and includes the underwriting agreement, legal opinion and related press releases as exhibits.